Mike Kramer

Investing Profile

Sweet spot: $25M Range: $10M–$40M

Vensana Capital thesis

Justin Klein is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin currently or previously served on the board of directors of Abrus Bio, Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate BioSciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), Evident Vascular, Intact Vascular (acquired), Luna Diabetes, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Relievant Medsystems (acquired), Senseonics (IPO), Topera (acquired), Ulthera (acquired), Ventaris Surgical, Vert

Sector and stage focus

  • Seed: Medical Devices, BioTech, Diagnostics, Drug Delivery, Digital Health
  • Series B: BioTech, Medical Devices, Diagnostics, Drug Delivery, Digital Health
  • Series A: Medical Devices, BioTech, Drug Delivery, Diagnostics, Digital Health
  • general: San Francisco Bay Area
  • Pre-seed: Medical Devices, Drug Delivery, Diagnostics, Digital Health, BioTech

Is Mike Kramer a fit for your round?

Upload your pitch deck and see whether Mike Kramer appears in your top 20 matches.

Find investors for your deck